7th NHS Oncology Conference: Exploring innovation and best practice
Book tickets
7th NHS Oncology Conference: Exploring innovation and best practice
Current Landscape:
One in every two people in the country is diagnosed with cancer at some point in their lives.
The NHS Long Term Plan aims to save thousands more lives each year by dramatically improving how we diagnose and treat cancer. The NHS’ ambition is, that by 2028, an extra 55,000 people each year will survive for 5 years or more following their cancer diagnosis.
The NHS Long Term Plan for Cancer states that ‘where appropriate every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan and health and wellbeing information and support.’
Importance and Timeliness of the Event:
393,000 people are diagnosed with cancer each year, on average someone in the UK is diagnosed every 90 seconds, with the number increasing every year. There is not a better time than now to act and make changes to these numbers bettering the lives of those living with cancer and bettering our healthcare system.
The Oncology Conference North aims to provide a secure and focused environment for NHS Oncology specialists to listen, learn and engage with peers and sector leaders from across the UK and further afield.
Key Content Streams:
- Developments in Radiotherapy - As the number of cancers diagnosed in the early stages increases, radiotherapy will play an increasing role in curing them.
- Proton Beam Therapy - Proton beam therapy is now in routine use in the UK, with recruitment ongoing for clinical trials to define the future benefits of this therapy. Artificial intelligence (AI) and improved computing power are making it faster to plan radiotherapy treatments.
- Anti-Cancer Drugs - Anti-cancer drugs are improving cure rates and can make many cancers into chronic diseases that people can live with. There is much research into combining new drugs with radiotherapy to increase the options for each patient.
- Genetic Mapping - enabling clinical oncologists to prescribe targeted, fully personalised systemic treatments and radiotherapy. By understanding and explaining genomics, the role of AI and the benefits and potential side effects of therapies, we can ensure each patient continues to receive truly personalised treatment that respects their individual beliefs, values and priorities.
- Addressing health inequalities in Oncology services - integrating personalised care strategies, including targeted outreach, education, and equitable access to advanced technologies to ensure a more inclusive and effective approach to cancer prevention and treatment.
Why Attend:
Our upcoming Oncology Conference North will open the floor to NHS professionals to come and discuss how the NHS is planning to lean on new models of delivery and innovation within the oncology sector. How the NHS plans to lean on new models of delivery and innovation to help manage the current backlogs and improve outcomes on a national scale.
Join us at The Oncology Conference North as we explore these new areas of best practice, network with peers and share insights.
Register now to be a part of this transformative journey and contribute to building a better future for healthcare.
Sponsors & Partners
- Developments in Radiotherapy
- Proton Beam Therapy
- Anti-Cancer Drugs
- Genetic Mapping: AI as a partner and tool, the role of Genomics in Oncology
- Cancer Standards: Models of care and measurement
- Improving outcomes and safety
- Early detection and screening
- New and Improved Cancer Targeted Therapies
- Addressing health inequalities in oncology services
- Advanced Registered Practice Nurse
- Anaesthesiologists
- Case Managers
- Chief Technology Officers
- Clinical Nurse Specialists
- Directors/Heads of Oncology
- Clinical Directors/Heads/Leads
- Medical Directors/Heads
- Medical Imaging Directors/Heads/Managers
- Pain Specialists
- Palliative Care Specialists
- Pathologists
- Paediatric Oncologists
- Radiologists
- Surgical Oncologists
- Urologists
- Pharmacologists
- Physicians
- Immunologists
- Chemotherapists
Your Pass Includes....
Your Pass Includes:
- Multiple live keynote presentations
- Live examples of both NHS and Commercial best practice
- Breakfast, Lunch and Refreshments included
- Meet the supplier sessions.
- Networking opportunity
- Live Q&A sessions with all speakers on the day
- Drinks receptions (subject to event)
- CPD accreditation
- Prize draws
Tickets For NHS Senior Managers
We have an invite only option for NHS Senior Managers for our conference, to see if you qualify for a complimentary place please click the button below.
Conference Speakers
Dr Anthony
Cunliffe
National Lead Medical Adviser and the Clinical Adviser for London at Macmillan Cancer Support
Joint Clinical Director for the South East London Cancer Alliance
Read biography
Dr Muhammad Babar
Aslam
Consultant pathologist and clinical lead digital pathology Wales
Betsi Cadwaladr University Health Board
Read biography
Fiona
Cook
Macmillan Personalised Care & Health Inequalities Lead
North Tees and Hartlepool NHS Foundation Trust
Read biography
Leah
Morgan
Personalised Care Lead & Cancer Improvement Facilitator
The Shrewsbury and Telford Hospitals NHS Trust
Read biography
Mike
Ryan
Head of the East Midlands Cancer Alliance
Chair of the East Midlands Radiotherapy Network
Read biography
Mr Henry
Cain
Consultant Oncoplastic Breast Surgeon
The Royal Victoria Infirmary, Newcastle Upon Tyne NHS Foundation Trust
Read biography
Naman
Julka-Anderson
Research Radiographer and Allied Health Professional Clinical Advisor
The Royal Marsden NHS Foundation Trust, Institute of Cancer Research and Macmillan Cancer Support.
Read biography
The programme
Registration and Breakfast
Registration and Breakfast
Navigating Health Inequalities: Personalised Care in Oncology Services within the NHS Panel Discussion
Navigating Health Inequalities: Personalised Care in Oncology Services within the NHS Panel Discussion
Explore the intersection of personalised care and health inequalities within the NHS oncology services in our panel discussion. Our experts will delve into the challenges and opportunities of delivering personalised cancer care, considering its impact on patient outcomes and potential disparities. Topics include ensuring equitable access, leveraging technology responsibly, promoting cultural competence, addressing policy implications, and prioritising patient advocacy.
Panellists:
-
Dr Anthony Cunliffe, National Lead Medical Adviser and the Clinical Adviser for London at Macmillan Cancer Support, Clinical Director for the South East London Cancer Alliance and the Oncology Lead at ORCHA (Confirmed)
-
Dr Emma Hyde, Clinical Director, Personalised Care Institute (Confirmed)
- Naman Julka-Anderson, Allied Health Professional Clinical Advisor, Macmillan Cancer Support (Confirmed)
-
Leah Morgan, Personalised Care & Cancer Improvement Facilitator Supporting those living with and beyond cancer (Confirmed)
-
Fiona Cook, Macmillan Personalised Care & Health Inequalities Lead, North Tees and Hartlepool NHS Foundation Trust (Confirmed)
Morning Break
Morning Break
Case Study - Oral Mucositis, results from 58 Photobiomodulation RCTs
Oral Mucositis is the most common and most significant side-effect of systemic chemotherapy and radiotherapy. The incidence is high (40-75%) and often leads to parenteral feeding and opioids, extended periods of hospitalisation, and a higher risk of systemic infection. Photobiomodulation (PBM) is a low-intensity light therapy treatment recommended by the Multinational Association for Supportive Care in Cancer (MASCC) and by The National Institute for Health and Care Excellence (NICE) guidelines in the UK for preventing or treating oral mucositis. Data from more than 50 randomised controlled clinical trials and our studies show that PBM can reduce the incidence of grade 3 or 4 Oral Mucositis by 75%. PBM utilises light in the red and near-infrared spectrum, which is absorbed by enzymes in mitochondria to increase cellular energy (ATP) production and simultaneously reduce oxidative stress (free radicals). The downstream effects act on gene transcription factor NF-κβ to reduce inflammatory cytokines and increase keratinocyte proliferation and migration leading to tissue repair. Treatment can be applied extra-orally and intraorally, ideally, five times a week before each fraction or RT or each infusion of CT (Monday-Friday); treatment times can be as short as five minutes per session. The benefits are improved quality of life and reduced total cost of care through reduced parenteral feeding, reduced use of opioids, and reduced rescheduling of cancer treatments. No adverse events have been reported, including no negative effects on survival or cancer reoccurrence.
Case Study - Pathway Innovation & Improvement in Radiation Oncology Services
Case Study - Icon
Keynote Presentation - Say Aye to AI: How could artificial intelligence applications aid breast cancer screening? (Confirmed)
Artificial intelligence (AI) may provide the opportunity to detect more cancers while reducing workload in breast screening. The University of Aberdeen along with colleagues at NHS Grampian and Kheiron Medical Technologies Ltd. have been evaluating how Mia, an AI tool, could be used in breast screening. Our retrospective evaluation using mammograms from women attending routine breast screening highlighted that the AI tool could detect more cancers if integrated into the screening pathway but was vulnerable to changes in the mammography machine software that would prohibit effective implementation into the screening pathways. Our recent results from the first UK AI in breast screening prospective study (GEMINI) has demonstrated that AI would improve cancer detection without increasing the number of women needing further evaluation and provide substantial workload savings.
Case Study - Optimising genomic testing using Oncotype DX® in the adjuvant breast cancer pathway
Case Study - Exact Sciences
Networking and Lunch
Networking and Lunch
Keynote Presentation - The Impact of Cancer Transformation Programmes (Confirmed)
Reflection: The Impact of Cancer Transformation Programmes
How the Faster Diagnosis Standard (FDS) improves patient outcomes and connects primary and secondary care clinicians.
The NHS established the Faster Diagnosis Standard (FDS) in 2022/23 with a framework toward a minimum standard 75% of patients referred for urgent suspected cancer to be advised of diagnostic results within 28 days of that referral. As cancer diagnostics and treatment are often complex, so are the pathways and processes used.
The East Midlands Cancer Alliance (EMCA) spans a 5.2 million population, x5 Integrated Care Systems (ICSs), x8 Acute/Tertiary Trusts, c100 primary care networks (PCNs) and c500 GP Practices, and has bridged secondary care and primary care initiatives and clinicians to significantly improve FDS for patients. Over 12 months, EMCA improved from 69% to 78% FDS whilst also seeing a 136% increase in referral demand and further treatment alongside building greater resilience.
Keynote Presentation - How AI revolutionising cellular pathology! (Confirmed)
Points for learning
- Learning about AI technology
- Impact on patient pathway
- Quality improvement in cancer diagnosis
Keynote Presentation - Health inequities for people of colour undergoing radiotherapy (Confirmed)
Health inequities for people of colour undergoing radiotherapy
Canapés, Drinks and Networking
Hot Buffet Food, Drinks and Networking
End of Day
End of Day
